WallStSmart

Enbridge Inc (ENB)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enbridge Inc generates 934% more annual revenue ($65.19B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 11.5%. EW appears more attractively valued with a PEG of 2.04. ENB earns a higher WallStSmart Score of 63/100 (C+).

ENB

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 4.7Quality: 4.5
Piotroski: 3/9Altman Z: 0.61

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENBUndervalued (+4.6%)

Margin of Safety

+4.6%

Fair Value

$54.02

Current Price

$53.59

$0.43 discount

UndervaluedFair: $54.02Overvalued
EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENB4 strengths · Avg: 9.3/10
EPS GrowthGrowth
294.9%10/10

Earnings expanding 294.9% YoY

Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Market CapQuality
$116.95B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

ENB4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
5.732/10

Expensive relative to growth rate

Free Cash FlowQuality
$-97.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.612/10

Distress zone — elevated risk

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ENB

The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : ENB

The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Key Dynamics to Monitor

ENB profiles as a value stock while EW is a growth play — different risk/reward profiles.

EW carries more volatility with a beta of 0.87 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

EW generates stronger free cash flow (-21M), providing more financial flexibility.

Bottom Line

ENB scores higher overall (63/100 vs 61/100). EW offers better value entry with a 69.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enbridge Inc

ENERGY · OIL & GAS MIDSTREAM · USA

Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?